Study reveals multiple high-risk genetic changes predict worse multiple myeloma outcomes across all treatments.
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...
New Innovative Local Treatment for Osteolytic Bone Disease in Multiple Myeloma Jan. 14 ... Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec. 5, 2024 — The first comprehensive ...
Researchers have discovered and analysed a rare but serious side effect of an innovative form of blood cancer therapy.
City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...
In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...
News Medical on MSN9d
Researchers investigate rare side effect of blood cancer immunotherapyResearchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback